IDO Pharm Co., Ltd., 41 Beonnyeong-ro, 15 beon-gil Danwon-gu Ansan-si Gyeonggi-do 15616 South KoreaFEI 3017021001Issued May 4, 2026Center for Drug Evaluation and Research (CDER)
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3017021001.
Violations4
Issue DateMay 4, 2026
Product TypeDrugs
StatusOpen
Letter Details
Firm
IDO Pharm Co., Ltd.
Location
IDO Pharm Co., Ltd., 41 Beonnyeong-ro, 15 beon-gil Danwon-gu Ansan-si Gyeonggi-do 15616 South Korea
FEI Number
3017021001
Country
South Korea
Issue Date
May 04, 2026
Issuing Office
Center for Drug Evaluation and Research (CDER)
Product Type
Drugs
Status
Open
Subject
CGMP/OTC Finished Pharmaceuticals/Adulterated
IDO Pharm Co., Ltd. FDA Warning Letter, May 4, 2026
Talk to a Specialist